Biotech Stocks: short review to Vertex Pharmaceuticals company, stocks and market in 2022.

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases

The Company’s marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Joshua Boger is the founder of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). He retired as Vertex’s Chief Executive Officer in May 2009, after over 20-years with the company.

3400 employees are in Vertex pharmaceuticals and The biopharmaceutical company makes its debut on the Fortune 500 this year, riding the wave of a 49% year-over-year revenue increase in 2020—driven primarily by its cystic fibrosis drugs Kaftrio and Trikafta.

VRTX Stock price in NASDAQ is about 228.8 USD in January 2022 and the company revenue is about 4.16 billion Dollar

Vertex Pharmaceuticals competitors include Biogen, MyoKardia and Bellicum Pharmaceuticals.

How much does a Senior Director make at Vertex Pharmaceuticals in California? Average Vertex Pharmaceuticals Senior Director yearly pay in California is approximately $246,729, which is 54% above the national average.

Biotech Stocks: short review to Vertex Pharmaceuticals company, stocks and market in 2022., Bio Data Technology: Bioinformatics and Biotechnology directory

Leave a Reply

Your email address will not be published.